Latest news
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeatMarketBeat · Sat, 08 Aug 2026 04:52:38 GMTCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeatMarketBeat · Fri, 07 Aug 2026 14:41:40 GMTState Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock TitanStock Titan · Fri, 07 Aug 2026 13:17:03 GMTCRVS Aug 2026 20.000 call (CRVS260821C00020000) interactive stock chart - Yahoo Finance AustraliaYahoo Finance Australia · Fri, 07 Aug 2026 08:10:54 GMTCRVS SWOT Analysis: Financial Losses and Growth Potential Revealed in 10-Q Filing - GuruFocusGuruFocus · Fri, 07 Aug 2026 07:56:16 GMTCorvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 05:09:15 GMTCorvus Eczema Trial Is Expected to Enroll About 200 Patients - Stock TitanStock Titan · Thu, 06 Aug 2026 23:04:17 GMTCRVS: Q2 2026 net loss rose to $18M as R&D spending increased; cash runway extends into Q2 2028 - TradingViewTradingView · Thu, 06 Aug 2026 20:05:40 GMT